The future of pathology isn’t just digital—it’s integrated. As precision medicine continues to advance, the need for seamless coordination between pathology and molecular diagnostics has never been greater. However, traditional…
A Summary of Staci Kearney’s presentation at the Digital Diagnostic Summit 2024 The Current State of the FDA’s Final Rule On May 6, 2024, the FDA issued its final rule…
AI has been a huge buzzword in pathology, but are the benefits worth the hype for prostate cancer? It’s true that AI can enhance digital prostate pathology by supporting diagnostic…
“We’re all doctors. We all got into this field for a reason: the patient is central to everything we do. Using Lumea technology simply results in a better end product…
Join us on PathPulse, the Digital Diagnostic Podcast, as we delve into the groundbreaking journey of Dr. Matthew O. Leavitt, a Stanford-trained pathologist and visionary leader in digital pathology. Host…
The benefits of digital pathology extend well beyond the pathologist’s workstation. When implemented effectively, digital pathology improves outcomes at every point in the diagnostic chain: patients receive faster, more accurate…
Bianca Collings Chief Marketing Officer Bianca Collings is Chief Marketing Officer at Lumea, where she leads GTM strategy, brand, product marketing, and SEO for the U.S. leader in primary clinical…
Lumea’s Digital Diagnostic Suite™ (Viewer+™) Receives FDA 510(k) Clearance* for Clinical Diagnosis LEHI, UTAH, UNITED STATES, March 18, 2025 /EINPresswire.com/ – Lumea, a leader in digital pathology solutions, is proud…
We’re excited to introduce the Digital Diagnostic Digest, a quarterly publication showcasing advancements in digital pathology and real-world applications with practical solutions. After seeing the year-over-year success of the Digital…
Lumea is excited to attend the USCAP 2025 Annual Meeting in Boston, Massachusetts, from March 22-27, 2025. As one of the premier events in pathology, USCAP is where leading minds gather to share insights,…
*BxLink has not been approved by the FDA for digital primary diagnosis. Refer to CAP guidelines regarding the use of digital pathology technologies.
